Evaluation of the Clinical Efficacy of PURESSENTIEL Allergy Protection Nasal Spray (SNPA®) in House Dust Mite Allergic Rhinitis- ACARAY Study

Main objective:

Testing the protective effect of SNPA on the nasal inflammatory allergic response in subjects with allergic rhinitis caused by dust mites.

The main objective of this clinical investigation is to evaluate the reduction in rhinoconjunctivitis symptoms following a nasal provocation test (Dermatophagoides pteronyssinus) performed after administration of Puressentiel Allergy Protection Nasal Spray, compared to those developed after administration of a placebo.

Secondary objectives

• Evaluate the difference in terms of nasal obstruction, measured by inspiratory nasal peak flow (INPF), after administration of the protective nasal spray and after placebo.
• Evaluate the duration of symptoms after performing the TPN and check whether there is a difference after the tests performed with the SPNA and with the placebo.

Méthodology

• 1 Type of study This is a prospective, single-center, crossover, randomized, double-blind, placebo-controlled study in adult subjects with allergic rhinitis caused by dust mites.
• 2 Main evaluation criteria The primary endpoint will be the difference between the validated symptom score for nasal provocation tests after performing the test with SPNA and with placebo.
• 3 Secondary evaluation criteria

• Difference between the value obtained with PFIN before TPN and after TPN and the difference between the results obtained when SPNA and placebo were administered beforehand.
• Difference between the duration of symptoms appearing after TPN with SPNA and with placebo
• 4 Scheduled visits and examinations

Two visits are planned, with at least 15 days (+7) between visits (washout period). During each of the two visits, patients will undergo a clinical assessment and nasal provocation tests. Before the tests begin, the clinical assessment will include:

• Rhinitis control test (ARCT) and asthma control test (ACT), if applicable;
• Nasal and conjunctival symptom score ;
• Nasal inspiratory peak flow (NIPF).

Each patient will receive two sprays per nostril of SPNA or placebo (saline solution), depending on randomization. Those who received SPNA during the visit on Day 0 will receive the placebo on Day 15, and vice versa. Thirty minutes after the administration of the spray, a nasal provocation test with Dermatophagoides pteronyssinus (LETI Pharma) will be performed according to the recommendations of the European Academy of Allergy and Clinical Immunology (EAACI).

For the nasal provocation test, the patient will be seated and at rest for 10 minutes before the start of the test. They will be informed about the test procedure, with particular emphasis on the fact that they must not breathe through their nose or sniff during the administration of the solutions. They will be warned of the various symptoms that may occur: tingling, sneezing, nasal discharge, and nasal congestion. The patient will be in apnea, with their mouth open. A spray of 0.3 HEP/ml will be administered into each nostril, followed by the placement of a nose clip, which will be removed after 10 minutes. A second dose of 3 HEP/ml will then be administered, following the same procedure as before. After 10 minutes, the nose clip will be removed. New assessments of nasal symptom scores and PFIN will be performed between the two doses of TPN, at the end of TPN, and 30, 60, 120, and 240 minutes after TPN.

Inclusion criteria

General inclusion criteria:

• The patient must have given their express consent to participate in the study.
• The patient must be affiliated with or a beneficiary of a health insurance plan.
• The patient is at least 18 years of age.

Inclusion criteria

for the target population:

• Patients who have already consulted the allergy department at Montpellier University Hospital.
• Patients suffering from perennial rhinitis (or rhino-conjunctivitis) caused by dust mites, diagnosed more than one year ago.
• In the case of asthmatic patients, asthma must be under control.
• Patients who have been able to stop all treatment with antihistamines or nasal corticosteroids for one week prior to the start of the study (7 days and 1 month, respectively).
• Patients covered by social security.

Exclusion criteria

5.4 Exclusion Criteria

General exclusion criteria:

• The patient is in a period of exclusion determined by a previous study.
• The patient is under judicial protection, guardianship, or curatorship.
• The patient is a minor.
• The patient is not fluent in French.

Exclusion criteria

regarding interfering diseases or conditions:

• The patient is pregnant and/or breastfeeding.
• Patient sensitized to a perennial allergen in addition to dust mites.
• Patient sensitized to a seasonal allergen, during the allergen's peak pollen season.
• Patient who has had a viral infection within 4 weeks prior to the provocation test.
• Patient treated or undergoing treatment with allergen immunotherapy.
• Patient treated with antihistamines (7-day washout period) or nasal corticosteroids (1-month washout period).
• Patients with severe uncontrolled asthma.